	US 11,718,645 B2
	Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment
Hendrik Luesch, Gainesville, FL (US); and Qi-Yin Chen, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Apr. 24, 2020, as Appl. No. 16/857,934.
Application 16/857,934 is a continuation of application No. 16/272,636, filed on Feb. 11, 2019, abandoned.
Application 16/272,636 is a continuation of application No. 15/120,356, abandoned, previously published as PCT/US2015/016743, filed on Feb. 20, 2015.
Claims priority of provisional application 61/942,495, filed on Feb. 20, 2014.
Prior Publication US 2020/0317732 A1, Oct. 8, 2020
Int. Cl. C07K 5/12 (2006.01); A61K 31/424 (2006.01); A61K 31/429 (2006.01); C07D 207/16 (2006.01); A61K 45/06 (2006.01); C07K 5/107 (2006.01); A61K 38/12 (2006.01)

CPC C07K 5/126 (2013.01) [A61K 31/424 (2013.01); A61K 31/429 (2013.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01); C07D 207/16 (2013.01); C07K 5/1016 (2013.01)]

20 Claims

1. A compound of formula 1:

or a pharmaceutically acceptable salt thereof;

wherein:

X is S or O;

each Y is independently H or optionally substituted alkyl;

Each R is independently alkyl optionally substituted with OH, OMe, SH, SMe, optionally substituted phenyl, NH₂, NH-alkyl, or N(alkyl)(alkyl); or each R is independently the side chain of a naturally-occurring or non-natural amino acid;

or wherein each Y and R and the adjacent atoms attached to them (nitrogen and carbon, respectively) can combine to form a heterocyclic ring;

R₁is optionally substituted alkyl;

R₂is H or optionally substituted alkyl; and

R₃is H, optionally substituted alkyl, or —C(O)alkyl.